Type 1 diabetes candidate shines at ADA 2019

10 June 2019
provention-bio-large

Immune-mediated disease specialist Provention Bio (Nasdaq: PRVB) has presented data from the At-Risk study, testing its type 1 diabetes (T1D) candidate PRV-031 (teplizumab).

Results from the study, which is evaluating the anti-CD3 monoclonal antibody for the prevention or delay of clinical T1D, were presented at the annual American Diabetes Association (ADA) meeting.

Results from the study showed that a single 14-day course of teplizumab significantly delayed the onset and diagnosis of clinical T1D, as compared to placebo, by a median of two years in children and adults considered to be at high risk.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology